I am going through the CROWN trial presentation, expertly presented at #ESMO20 by @bensolomon1. Also kudos to @EnriquetaFelip @JulienMazieres @TonyMok9 and the rest of the authors (those were the ones I could find on twitter). This is an important study, and analysis is complex Here, of course, is the slide everyone is talking about. HR 0.28 for PFS favoring lorlatinib. This is undoubtedly an impressive HR, but how do these data compare to prior series and studies? #LCSM

OK now @DrSteveMartin is going to walk me through some exciting new abstracts in EGFR Exon 20 insertion. I always enjoy his talks - I am excited! #LCSM #ASCO20 The first topic that he discussed is the abstract by @ZPiotrowskaMD and colleagues. From preclinical models osimertinib might have some efficacy. In contrast to many other TKI's in this space, we know that osimertinib is well tolerated (even at the 160 mg dose) #LCSM #ASCO20